News and Trends 16 Oct 2019 GammaDelta Therapeutics Spins Out Cancer Immunotherapy Biotech The UK biotech GammaDelta Therapeutics has founded Adaptate Biotherapeutics to develop cancer immunotherapies based on antibodies that boost a rare type of immune cell. Adaptate Biotherapeutics is a spin-out of GammaDelta Therapeutics, a London company founded in 2016 that specializes in using a rare type of immune cells, known as gamma delta T-cells, to fight […] October 16, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 11 Jun 2019 Gamma Delta T Cells: A New Hope Against Cancer A new wave of therapies based on a unique type of immune cells, called gamma delta T cells, has the potential to treat cancer with stronger responses and fewer side effects. Immunotherapies based on T cells are becoming a huge trend in the treatment of cancer, especially CAR-T cells. These genetically-modified T cells have shown […] June 11, 2019 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jul 2018 Abingworth Closes €268M to Invest in Life Science Companies Abingworth has closed $315M (€268M) for its most recent fund, Abingworth Bioventures VII, which invests in European and US life science companies. In the current fundraising, Abingworth surpassed its target of $300M. The new fund will invest in life science companies in all stages of development, including early and late-stage venture deals. The company plans to […] July 9, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Interview 24 Jul 2017 Discussing Open Science with the Head of Translation at The Francis Crick Institute Officially opened less than a year ago, The Francis Crick Institute is already conducting top-level biomedical research, has launched two spin-outs and struck research partnerships with both AstraZeneca and GlaxoSmithKline. I spoke to the Head of Translation, Dr. Véronique Birault, to learn more about the Crick’s unique model of translation and the key for its […] July 24, 2017 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 12 Jun 2017 This Italian Academic-turned-CEO also Launched 7 Cancer Drugs at GSK Paolo Paoletti might have been forced to reconsider his career as a professor in medicine, but academia’s loss was biopharma’s gain! Before becoming CEO of one of London’s most exciting biotechs, GammaDelta Therapeutics, Paolo Paoletti had a long run through the corporate ranks of pharma. He was coaxed out of academic medicine to join Eli […] June 12, 2017 - 9 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 9 May 2017 British Biotech Startup Partners with Takeda to Advance its T Cell Platform GammaDelta Therapeutics and Takeda have formed a strategic collaboration to develop a novel T cell platform, which is based on gamma delta (γδ) T cells. Based in London, GammaDelta Therapeutics builds on the work of Adrian Hayday and Oliver Nussbaumer of Kings College London and The Francis Crick Institute. Backed by the huge British VC […] May 9, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2016 Abingworth launches UK Immuno-Oncology Startup with Seed Funding Just when we thought it couldn’t become any more intense, the field of immuno-oncology is heating up. VC giant Abingworth has seeded a new UK startup, GammaDelta Therapeutics, to bring its T cell therapy to the clinic. Abingworth, a huge British VC firm, has thrown its weight behind a new London-based immuno-oncology startup, GammaDelta Therapeutics. […] September 19, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email